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Abstract
Purpose of Review This review summarizes the fungal diag-
nostic measures currently available for use in paediatric pa-
tients at high risk for developing invasive fungal disease (IFD)
and those suspected of having an IFD. The clinical utility of
each test is described based on reported performances of indi-
vidual tests in specific paediatric populations.
Recent Findings Available studies in the paediatric population
are scarce and are characterized by a huge heterogeneity in
underlying diseases (e.g. different risk for IFD), different
study objectives and management strategies (screening versus
diagnostic) used.
Summary A final valuation of paediatric studies on fungal
diagnostic tools is limited. While the galactomannan and fun-
gal PCR assays are useful to exclude the presence of IFD, it is
unclear if mannan, mannan antibodies and β-D-glucan are of
benefit due to a lack of studies or validation of the cut-off,
respectively. Well-designed multicentre paediatric studies are
urgently needed to improve the outcome of IFD.
Keywords Invasive fungal disease . Diagnostics . Paediatric
patients . Imaging . Galactomannan . PCR
Introduction
A timely diagnosis of invasive fungal disease (IFD) in
children is a real challenge due to difficulties encountered
in obtaining enough sample volumes, the need for anaes-
thesia to perform certain diagnostic procedures, and
sparse clinical data with respect to the usefulness of fun-
gal biomarkers and molecular detection methods. Culture
and/or histopathological evidence of tissue invasion by
the fungus is the gold standard to diagnose an IFD and
is classified as proven disease [1]. Fungal biomarkers (in-
cluding galactomannan, mannan and β-D-glucan) and
fungal species-specific or pan-fungal PCR have been de-
veloped as tools both to enhance an early diagnosis of
IFD as well as to increase the likelihood of the presence
of an IFD. Several PCR based methods for the detection
of resistance profiles including mutations conferring resis-
tance to specific antifungals (e.g. azole resistance in
A. fumigatus, echinocandin resistance in Candida spp.)
are available as well. In addition, imaging modalities, in
particular in the diagnosis for invasive pulmonary asper-
gillosis and to assess dissemination of a specific IFD, play
an important role in the diagnostic process of a suspected
IFD. It has been recognized that the performance and
usefulness of both the more conventional as the newer
fungal diagnostic tools in paediatric patients may differ
from those in adults. This has led to 2 paediatric specific
European guidelines for the management of IFD [2••,
3••]. At present, the EORTC-MSG definitions for the di-
agnosis of IFD undergo a second revision in which pae-
diatric specific diagnostic recommendations will be in-
cluded. The present review will focus mainly on paediat-
ric specific studies in which the performance of a specific
fungal diagnostic test has been evaluated.
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Fungal Culture & Histopathology
The sensitivity of blood cultures to detect candidaemia ranges
between 21 and 71% as reported in autopsy studies [4] and is
believed to be lower for neonates and infants due to sample
volume issues. The ESCMID/EFISG guideline recommends
to take 3 blood samples with a minimum volume of 2 ml each
in childrenwith a bodyweight < 2 kg and 6ml each if between
2 and 12 kg to ensure a 50–75% sensitivity to detect Candida
[5]. It may be obvious that these recommendations are impos-
sible to be followed for (premature) neonates. Blood cultures
are further limited by slow turn-around time and will not be
positive in deep seated Candida infections including
hepatosplenic candidiasis. Aspergillus species are rarely cul-
tured from blood samples [6], and diagnostic accuracy of his-
topathological examination is below 80% [7]. Although most
moulds are hardly recovered from blood cultures, positive
blood cultures are more often obtained in IFD caused by
Scedosporium spp., Fusarium spp. and Acremonium spp.
(among others) due to the formation of spores during invasive
growth. Mycological culture of BAL fluid in case of pulmo-
nary mycoses has a low sensitivity of between 34% and 50%
[8, 9]. Although histopathological examination will enhance
differentiation between classes of moulds based on character-
istic morphologies (e.g. Aspergillus species versusMucorales)
during invasive tissue growth, culture and/or molecular detec-
tion methods are needed to identify the causative fungus [8].
Often concerns are raised about the feasibility and safety of
performing invasive diagnostic procedures in children and the
added diagnostic value. It has been demonstrated though, that
both bronchoscopy and lavage as well as CT-guided transtho-
racic biopsies can be performed safely in children and leads to
more accurate and causative diagnosis of invasive fungal dis-
ease [10, 11]. Specific fungal agars to detect individual
Candida species (chromogenic agars) or to detect azole-
resistant Aspergillus species (4-wells agar plates,
VIPcheck™) [12] will enhance timely identification and
targeted antifungal therapy.
Fungal Biomarkers
Galactomannan
Galactomannan (GM) is a carbohydrate constituent of the
Aspergillus cell wall that is released by all Aspergillus spp.
during growth. This polysaccharide can be detected by a com-
mercially available, FDA-approved enzyme immunoassay
that incorporates the ß-1–5 galactofuranosyl specific EBA2
monoclonal antibody as a detector for GM (Platelia™
Aspergillus, Bio-Rad). Cross-reactivity has been observed
for a number of other fungi (e.g., Penicillium spp., Fusarium
spp., Histoplasma capsulatum, Cryptococcus neoformans),
Bifidobacterium spp. and some batches of β-lactam antibi-
otics. On the other hand, non-angio-invasive aspergillosis as
is seen in non-neutropenic immunocompromised patients and
systemic mould-active antifungal prophylaxis have been asso-
ciated with false-negative test results [13].
Initial studies clearly showed the usefulness of this test in
the early detection of invasive aspergillosis (IA) with positive
test results in neutropenic patients before clinical signs and
symptoms, including CT-chest abnormalities, develop [13].
Galactomannan testing can be used both as a screening tool
in patients considered at high risk for developing IA as well as
a diagnostic tool in patients suspected of having developed IA
[14, 15••]. It is included as a mycological criterion in the
revised 2008 EORTC/MSG consensus diagnostic definitions
[1], and GM testing is recommended by a number of current
guidelines for early diagnosis and timelymanagement of IA in
both adult and paediatric patients [2••, 16].
A reasonable number of studies have assessed the useful-
ness of GM testing either as a screening tool or as diagnostic
test for IA in defined paediatric populations in which the
EORTC/MSG definitions were used to classify the probability
of IFD (Table 1). Most of the studies were performed either to
evaluate GM as a screening strategy in patients at high-risk for
IFD according to their underlying malignancy, or as a diag-
nostic strategy in patients having a high clinical suspicion for
IFD based on persistent febrile neutropenia not responding to
broad spectrum antibiotics. Most of the study populations
consisted of patients with underlying haematological malig-
nancies and patients after haematopoietic stem cell transplan-
tation (HSCT), and to a lesser extent, patients suffering from
solid tumours, which, in general, have a lower a-priori risk for
IFD than children with leukaemia and children undergoing
HSCT. The studies included between 46 and 198 patients,
assessing between 136 and 1865 samples, respectively. Only
3 of the studies in which GM testing was part of a screening
strategy were performed in neutropenic children [17–19]. GM
testing has not been validated in non-neutropenic patients and
in the clinical setting the value of GM testing differs clearly
between neutropenic and non-neutropenic patients [20].
The comparison of the studies is limited by the heterogene-
ity, such as by different definitions of test positivity (e.g, per
sample or per 2 consecutive samples), and by the heterogeneity
of the cut-off (e.g., optical density of 0.5 or 0.7). Similarly, the
number of patients with proven/probable IFD vary widely be-
tween the studies (median 5.5; range, 1–23) as well as the
prevalence of IFD in the various centres. Due to the heteroge-
neity in study design and study population, it is not surprising
that there is a wide range of reported sensitivity and specificity.
Combining the study results from the 5 studies in which GM
was used as a screening tool only [17–19, 21, 22], sensitivity
and specificity ranges from 0 to 90% (median 65%) and 66 to
95% (median 87%), respectively. Adding the 3 studies in which
GM was used both as a screening and diagnostic measure
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[23–25], sensitivity and specificity ranges from 0 to 100% (me-
dian 72.5%) and 66 to 98% (median 89.5%), respectively. Only
2 paediatric studies did use serum GM as a diagnostic tool in
children with prolonged febrile neutropenia showing a compa-
rable sensitivity of 84% and 95%, but a clearly different spec-
ificity of 38% and 80% [26, 27]. These data favourably com-
pare with the results given in a recent meta-analysis for GM
testing in adults [sensitivity 0.82 (95% CI 0.73 to 0.90) and
specificity 0.81 (95% CI 0.72 to 0.90)] [15••].
A limited number of studies have been performed on
the evaluation of GM in other body fluids, such as
broncho-alveolar lavage (BAL) fluid or cerebrospinal flu-
id (CSF). Two retrospective studies in immunocompro-
mised children assessed the value of GM testing in BAL
fluid for the diagnosis of invasive pulmonary aspergillosis
(IPA) [10, 28]. Using a cut-off index of ≥0.5, a sensitivity
of 82.4% and 78% was reported, with a specificity of
87.5% and 84%. These results do support the use of
GM testing in BAL fluid if IPA is suspected based on
clinical signs and symptoms and are comparable to those
reported in adult high-risk haematology patients [29].
The utility of GM testing in the diagnosis of CNS aspergil-
losis in children is supported only by small retrospective case
reports and case series [30, 31]. In one study, GM levels in the
CSF in 5 patients with probable CNS aspergillosis were sig-
nificantly higher than those of 16 control patients indicating
the potential diagnostic value of GM in CSF [30].
In addition to its diagnostic use, serial serum GM assess-
ments can used to monitor the effectiveness of antifungal ther-
apy [32, 33]. Although these studies did not include paediatric
patients, the possibility to identify patients failing antifungal
therapy early during the course of IA will facilitate prompt
interventions (e.g. optimizing dosages, switch to different an-
tifungals) and optimize outcomes. Recently, Huurneman et al.
aimed to develop a pharmacokinetic-pharmacodynamic mod-
el linking the PK of voriconazole in 12 paediatric patients
suffering from IAwith GM measurements. Such an approach
does take into account that the voriconazole plasma level as-
sociated with a decreasing GM in an individual patient is
predictive of a favourable outcome, and not the voriconazole
level per se [34•].
β-D-Glucan
Whereas GM has the limitation of being able to detect only
IA, β-D-glucan (BDG) as a cell wall component of many
pathogenic fungi can be detected in invasive infections due
to Aspergillus spp., Candida spp., Pneumocystis jirovecii,
Fusarium spp., Trichosporon spp. and Saccharomyces spp.,
whereas it is absent in mucormycosis. Similar to GM, BDG is
included as mycological criterion in the revised definitions of
IFD from the EORTC/MSG consensus group [1]. Studies in
adults suggest that monitoring of BDG might be a useful
method to exclude IFD in clinical environment with low to
moderate prevalence of IFD. Many potential sources for con-
tamination have been demonstrated and may lead to false-
positive results [35••]. A meta-analysis showed a pooled sen-
sitivity and specificity of BDG of 76.8% (95% CI, 67.1%–
84.3%) and 85.3% (95%CI, 79.6%–89.7%), respectively, and
importantly, no major differences in the sensitivity of BDG
testing for the detection of invasive Candida or Aspergillus
infections were observed [36].
The first studies in children haves shown that mean BDG
levels are higher in immunocompetent uninfected children
than adults [37], that Candida colonization of the gut in pae-
diatric cancer patients leads to increased serum BDG (82–
141 pg/ml) [38], and that very high levels of BDG exists in
neonates and children with proven IFD [39]. Goudjil et al.
showed that the optimal BDG cut-off for the identification
of neonates with invasive candidiasis was 125 pg/ml (and
not 80 pg/ml as suggested for adults) resulting in a sensitivity
and specificity of 84% and 75%, respectively [40]. Two pae-
diatric studies assessing the value of serum BDG in the diag-
nosis of IFD (mainly IA) showed that this test is not a reliable
efficient diagnostic tool in the paediatric patients with hema-
tologic disorders (n = 62) and HSCT recipients (n = 34) due to
a high number of false-positive and false-negative results
when 80 pg/ml was used as the cut-off (Table 1) [18, 41•].
Due to the paucity of data on BDG in children and the need to
validate a paediatric specific cut-off, current guidelines recom-
mend that BDG should not be used to guide paediatric clinical
decision making [2••].
Mannan and Anti-Mannan Antibodies
Mannan, a Candida cell wall component, and anti-mannan
antibodies, have been used as a target for serological tests
and are specific biomarkers for the detection of invasive can-
didiasis. Sensitivity is species-dependent and lower for
C. parapsilosis and C. krusei (4–50%) than for C. albicans
and C. tropicalis [42, 43], which needs to be taken into ac-
count when used in neonatal and paediatric populations.
Mannan antigen detection alone shows an excellent specificity
(97.5%) but is offset by an unacceptable low sensitivity
(58.9%). Combination of mannan antigen and anti-mannan
antibodies increases the sensitivity to 89.3% but will be at
the cost of lowering the specificity to 63% [44]. Paediatric
specific data is not available and only 1 smaller study included
a restricted number of children [45]. Interestingly, the influ-
ence of Candida colonization in children with cancer on the
performance of the mannan antigen assay has been studied
and showed not to give rise to significant levels of mannan
in the circulation [38]. Mannan antigen testing in serum and
CSF may be of value to diagnose hepatosplenic candidiasis
(blood cultures are rarely positive) and Candida meningitis,
respectively [46, 47].
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Molecular Fungal Tools
The lack of standardization and absence of validated commer-
cial systems of PCR-basedmethods for the detection of fungal
pathogens resulted in the exclusion of PCR testing in the re-
vised 2008 EORTC/MSG diagnostic criteria [1]. However,
collaborative efforts (Fungal PCR Initiative, FPCRI) have
led to the provision and widespread clinical evaluation of op-
timal standardized and validated protocols of the Aspergillus
PCR and is proposed to be included in the revised EORTC/
MSG diagnostic criteria [48]. Several commercial Aspergillus
PCR assays are available which will provide a standardized
approach if combined with the FPCRI recommendations.
Blood and BAL fluid samples are most commonly tested by
PCR for the purpose of screening high risk patients and diag-
nosing IPA, respectively. The test characteristics of the
Aspergillus PCR showing a greater specificity for BAL fluid
while a significantly greater sensitivity was demonstrated for
blood [48]. Sensitivity and specificity of Aspergillus PCR in
blood samples are 81% and 79%, respectively, as shown in a
recent meta-analysis [49••].
A total of 9 paediatric studies were recently reviewed in
which a PCR-based assay was used in children at high-risk or
suspected of IPA [50•]. An Aspergillus specific PCR used as a
screening tool in haematology patients at high risk for IAwas
evaluated in 2 studies and demonstrated a high negative pre-
dictive value [18, 23]. The other 6 studies assessed the use of a
PCR assay (4 Aspergillus specific, 2 pan-fungal) as a diagnos-
tic tool in immunocompromised children suspected of having
IPA and showed overall a wide range of sensitivities (34%–
96%) and specificities (37%–96%) (Table 1) [51–56].
Comparable efforts have been made to improve the detec-
tion of Candida spp. in patients with invasive candidiasis.
Pooled sensitivity and specificity for suspected invasive candi-
diasis are 95% and 92%, respectively [57]. Several studies have
shown that PCR results preceded positive cultures significantly,
led to earlier initiation of antifungal therapy (median of 3 days)
and showed to have prognostic value [4]. Scarce data is
supporting the clinical utility of Candida PCR assays for the
early and improved detection and identification of invasive
candidiasis in neonates and children [58, 59]. Two commercial
Candida PCR assays are currently available. One is a multiplex
PCR assay detecting 19 bacteria and 6 fungi (SeptiFast) which
showed a sensitivity of 61% and a specificity of 99% for the
detection of candidaemia in adult patients with sepsis [60]. In a
large paediatric study using SeptiFast to diagnosis septicaemia,
the rate of positive results was significantly higher by this PCR
assay (14.6%) compared to culture (10.3%), with a specific
higher rate of detection of Candida spp. [61]. The recently
FDA-approved T2 detection methodology using magnetic res-
onance to detect Candida colony-forming units is promising
for the detection of invasive candidiasis in adults [62•]. A clin-
ical study (NCT02220790) called “BIOmarkers in Paediatric
Invasive Candidiasis” (BIOPIC) will prospectively enrol 500
children at high risk for developing invasive candidiasis and
test 4 currently approved molecular assays for the detection of
Candida spp. including the T2Candida platform.
Several PCR based methods for the detection of fungal
pathogens including mutations conferring resistance to specif-
ic antifungals (e.g. echinocandin resistance in Candida spe-
cies and azole resistance in Aspergillus fumigatus) are also
currently available and will further enhance early targeted an-
tifungal therapy [63, 64].
A potential drawback of PCR testing in the paediatric pop-
ulation is the amount of specimen needed to perform valid
testing (about 2 ml), which is markedly more material than
that needed for the GM (600 ul, including serial retesting),
BDG (about 200 ul, including serial retesting), and the lateral
flow device (LFD) (100 ul) tests.
Imaging Modalities
Chest computed tomography (CT) plays an important role in
the early diagnosis of invasive mould infections, in particular
invasive aspergillosis, as the vast majority of those infections
are localized in the lungs. Characteristic CT findings for IA
including particular nodules with halo sign, air crescent sign
and cavitation have been described in adults and are included
as clinical criterion in the revised EORTC/MSG definitions [1,
65]. Those findings are however not restricted to IA and can
also be caused by other moulds. The so-called reversed halo
sign has been described as an early sign of invasive
mucormycosis and may assist differentiation between those
2 groups of moulds exhibiting different antifungal susceptibil-
ities [66]. In children, those typical signs are often not ob-
served and radiographic findings are more unspecific
(Table 2) [67–69]. The appearance of new abnormalities on
the CT-chest during febrile neutropenia not responding to
broad spectrum antibiotics should therefore be considered as
possible IFD in children.
Screening patients with probable or proven invasive pul-
monary aspergillosis by magnetic resonance imaging (MRI)
of the brain is recommended even in the absence of neurolog-
ical signs and symptoms [70, 71•]. Dissemination of IPA to
the CNS has been reported to be as high as 14% and clinical
signs and symptoms only developed late in the course of the
disease [72, 73]. Although existing guidelines do not recom-
mend screening of extra-pulmonary sites in the absence of
localized signs or symptoms, early detection of cerebral
localisations of IA, followed by targeted treatment regarding
the choice and dose of an antifungal with sufficient CNS pen-
etration, including surgery in selected patients, will improve
the dismal outcome of CNS aspergillosis.
Imaging modalities are crucial in the diagnosis of
hepatosplenic candidiasis (= chronic disseminated candidiasis),
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a distinct phenotype of deep seated candidiasis localized main-
ly in the spleen and liver, affecting neutropenic patients with
children being specifically at risk for this form of invasive
fungal disease [74, 75]. MRI appears to be superior to both
CT and ultrasound but due to the lack of an inflammatory
response during neutropenia initial imaging results are often
negative. Repeated imaging is required after neutrophil recov-
ery to improve the diagnostic accuracy [76•].
Future Perspectives
Lateral-flow device technology allows for rapid and bed-side
testing with minimal technical expertise. For the diagnosis of
IA, an immunochromatographic LFD using a monoclonal an-
tibody (JF5) specific for a glycoprotein antigen release during
active growth of A. fumigatus has been developed [77].
Preclinical data has shown that the test is highly specific,
reacting with antigens from various Aspergillus species, but
not with antigens from a large number of clinically important
fungi including Candida spp., Fusarium solani, Rhizopus
oryzae and Cryptococcus neoformans. Clinical experience
with this new LFD is limited and only 2 studies in adults have
evaluated the performance of this LFD on serum samples
compared to real-time PCR and GM enzyme immunoassay
[78, 79]. Comparable specificity (98% vs 95.5% and 91.5%
for PCR and GM, respectively) and sensitivity (81.8% vs
95.5% and 77.3% for PCR and GM, respectively) were ob-
served. In combination with PCR, a 100% sensitivity and
specificity could be reached to differentiate proven/probable-
IA from no-IA [79].
A high diagnostic potential of the LFD in BAL samples
compared to PCR, GM, BDG and culture, in differentiating
patients with proven and probable IA (17 patients) versus no
IA (44 patients), was shown in adults [9]. Sensitivity of the
LFD was slightly higher compared to PCR and GM (80% vs.
70%), while the specificity was comparable (between 95%
and 100%). Combining either GM and PCR or GM and
LFD resulted in an increased sensitivity (100% and 94%, re-
spectively). Johnson et al. compared the diagnostic accuracy
of the LFD with those of a real-time PCR (qPCR) and GM in
BAL from patients with proven IA (n = 8) versus no IA
(n = 15). The LFD showed a higher sensitivity and specificity
when compared to GM (100% vs 87.5% and 80% vs 66.7%,
respectively) and comparable sensitivities and specificities
when compared to the qPCR used. Combined use of the
LFD and qPCR did not improve the test characteristics any
further [80]. Paediatric studies are still awaited.
In addition to searching for more sensitive and specific
fungal biomarkers predicting IFD, identification of host re-
sponse biomarkers may contribute to an early diagnosis of
IFD. Discovery of IPA specific host response biomarkers have
recently been described in a cohort of leukaemic adult patients
receiving chemotherapy. The authors showed that by
intergration of the host biomarkers with GM testing, the de-
tection of probably IPA could be improved [81•].
Although the chest CT scan has a prominent role in diag-
nosing IPA, a clear differentiation between classes of causa-
tive pathogens is impossible, neither as is the differentiation to
the underlying disease. New imaging modalities using specif-
ic radiopharmaceuticals are a promising tool for the detection
of IA. In the pathophysiology of A. fumigatus infections, iron
plays an essential role. Iron transporter mechanisms employed
by A. fumigatus involve iron binding siderophores. By
exchancing the iron for the radionuclide Gallium 68 (68Ga),
siderophores can be labelled and visualized by the use of
Positron Emission Tomography (PET) [82, 83]. In pre-
clinical studies it has been shown that the use of 68Ga-labelled
siderophores are specific targeting A. fumigatus and uptake is
significantly lower in other fungal species and almost zero in
other micro-organisms or cancer cells [84•]. Another approach
is the use of A. fumigatus-specific antibodies labelled with a
radionuclide to be visualized by PET/MR (magnetic reso-
nance) imaging. By conjugating the A. fumigatus-specific
monoclonal antibody JF5 with the chelator DOTA and then
labelling with Copper 64 (64Cu), Rolle et al. were able to
Table 2 The spectrum of
radiographic abnormalities in
paediatric patients with probable
and proven invasive aspergillosis
Burgos 2008 [69]
9.9 yrs. (0–18 yrs)
12% PID
88% cancer
Thomas 2003 [68]
5 yrs. (7 mo – 18 yrs)
50% PID
50% haem-onc
Taccone 1993 [67]
11 yrs. (7–18)
100% haem-onc
CT- chest (125) X-thorax (18) CT-chest (8) CT-chest (14)
nodules 65 (52%) 4 (22%) 4 (50%) 8 (57%)
halo sign 12 (10%) - - 2 (14%)
air-crescent sign 3 (2.5%) - - 4 (29%)
infiltrates 39 (31%) 14 (78%) 2 (25%) 8 (57%)
cavities 27 (21%) - - 3 (21%)
other 42 (34%) 5 (28%) - -
PID, primary immunodeficiency; haem-onc, haemato-oncology
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specifically detect IPA. In addition, by using this newly devel-
oped PET tracer, IPA could be distinguished from bacterial
lung infections and nonspecific lung inflammation [85]. Of
note, the same monoclonal antibody (JF5) was used as is
present in the LFD.
Conclusions
The clinical assessment of the various fungal diagnostic tools
currently available are lacking behind in the paediatric popula-
tion. Due to the fact that there are clear differences in underlying
conditions and in terms of the epidemiology of IFD, the perfor-
mances and clinical utility of the various tests used in the diag-
nosis of IFD may differ from those observed in adults [86]. In
addition, the feasibility of performing invasive diagnostics and
obtaining large enough sample volumes is more challenging in
neonates and children. The paediatric studies performed to date
with GM and fungal PCR are supportive of its use to rule out
IFD due to their high negative predictive values as also seen in
adult patients. For the β-D-glucan assay, a paediatric specific
cut-off needs to be validated before this assay can be of clinical
use in neonates and children. There are no studies assessing the
value of mannan and mannan antibodies in the diagnosis of
invasive candidiasis. Due to the central role the performance
of chest CT scans has in the diagnosis of IPA in neutropenic
patients, a paediatric study is urgently needed to confirm if the
characteristic ‘halo sign’ and ‘air-crescent sign’ is indeed age-
specific. Individual centres need to decide if the available fungal
diagnostic tests will be employed in a screening strategy to rule
out IFD (and thereby preventing overuse of antifungals) or a
diagnostic test to rule in disease (targeted therapy). Positive
arguments can be found for each strategy and depend on the
underlying risk of IFD, prevalence and pre-test probability of
disease and use of antifungal prophylaxis.
Overall, a final valuation of paediatric studies is clearly
limited by several factors such as 1) small and inhomogeneous
patient populations (e.g., haematological versus non-
haematological malignancies; neutropenic versus non-
neutropenic patients differing in the risk for IFD), 2) different
study objectives (e.g., screening of patients without signs and
symptoms of IFD versus diagnostic work-up of patients with
suspected fungal infections), 3) different, often non-
comparable PCR methods and 4) the evaluation of different
samples such as blood, BAL fluid or CSF.
A multicentre trial to assess the use of non-culture based
fungal diagnostic tools in which the shortcomings of the stud-
ies to date are overcome, is of utmost relevance to validate its
use in the paediatric population. This trial needs to enrol a
homogenous patient population at high risk for IFD, and for
the analysis one needs ideally patients in whom IFD will be
proven or ruled out during the study period. This trial will
require a multicenter setting, but institutions have to be
comparable regarding standardized diagnostic algorithms
and procedures. In addition, optimal management strategies
utilizing multiple diagnostic tools to increase performance and
different approaches (e.g. screening versus diagnostic) to en-
able justified use of antifungals, reducing toxicity and costs. A
recently initiated first paediatric trial is underway to assess the
value of β-D-glucan, Candida T2 assay, mannan and mannan
antibodies for the diagnosis of invasive candidiasis in paedi-
atric patients, led by the International Paediatric Fungal
Network (www.ipfn.org).
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